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Abstract
Background—The uptake of inhaled particulate matter by airway phagocytes is an important 
defence mechanism contributing to the clearance of potentially toxic substances, including 
aeroallergens, from the lung. Since airway monocytes and macrophages can also function as 
antigen presenting cells, their ability to engulf materials deposited on the airway surface is of 
particular interest in patients with allergic asthma. To determine whether airway mononuclear 
phagocytes of patients with allergic asthma might have enhanced phagocytic activity, the in vivo 
uptake of inhaled radiolabelled particles was compared in 10 patients with mild allergic asthma 
and 8 healthy (non-allergic) individuals.
Methods—Phagocyte function was assessed by quantifying the proportion of radioactivity 
associated with cellular and supernatant fractions of induced sputum 2 h after inhalation of 
radiolabelled sulfur colloid particles. All subjects were pretreated with albuterol before sputum 
induction. A standardised breathing pattern was used to target aerosol deposition in the bronchial 
airways.
Results—In vivo particle uptake by airway cells was significantly greater in patients with asthma 
than in healthy volunteers (57.2% (95% CI 46.5% to 67.9%) vs 22.3% (95% CI 4.9% to 39.6%), 
p<0.01), as was in vitro phagocytosis of opsonised zymosan-A bioparticles. There was also a 
significant correlation (r = 0.85, p<0.01) between the percentage of sputum mononuclear 
phagocytes and the percentage uptake of particles in the patients with asthma but not in the control 
subjects.
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Conclusions—In vivo particle uptake by airway macrophages is enhanced in persons with mild 
asthma. Enhanced uptake and processing of particulate antigens could contribute to the 
pathogenesis and progression of allergic airways disease and may contribute to the increased risk 
of disease exacerbation associated with particulate exposure.
Epidemiological studies have shown that particulate matter in the respirable range of ≤10 
μm aerodynamic diameter (PM10) is associated with a variety of adverse health effects1 
including respiratory and cardiovascular disease, and have demonstrated a link between 
particulate air pollution and exacerbations of asthma.2 There is also evidence that particles 
may serve as carriers for biological materials such as endotoxin3 and aeroallergens, and that 
they may also function as adjuvants4 by inducing airways inflammation resulting in a 
“priming” of airway leucocytes involved in airways allergic responses.
Airway mononuclear phagocytes represent one of the first lines of cellular defence against 
inhaled particulate material including pathogens and allergens, and also probably participate 
in recall immune responses to either pathogen antigens or allergens. We have previously 
shown that sputum macrophages from subjects with more severe asthma had impaired 
phagocytic capacity compared with subjects with less severe asthma and healthy 
volunteers.5 In vitro phagocytosis assays, however, may not accurately reflect the in vivo 
process which occurs within the airway surface liquid milieu and is influenced by the 
presence of phagocytosis-modulating factors. Thus, an in vivo methodological approach is 
needed to assess accurately whether subjects with asthma have constitutively modified 
particle uptake compared with healthy controls.
We and others have shown that sputum macrophages in healthy individuals rapidly engulf 
inhaled particles.67 Radiolabelled aerosols and induced sputum68 were used to examine 
possible differences in the uptake of inhaled particles by airway phagocytes in patients with 
mild asthma and healthy volunteers.
METHODS
Detailed descriptions of the methods used in this study can be found in the online 
supplement.
Subjects
Eight healthy non-smoking volunteers aged 19–50 years (5 men, 3 women) and 10 subjects 
with mild atopic asthma aged 22–46 years (2 men, 8 women) were recruited to participate in 
the study. All subjects had to be able to produce an adequate induced sputum sample (at 
least 5×105 cells) during their screening visit to participate in the study. They had all been 
free of respiratory tract infections for 6 weeks before beginning the study and had a forced 
expiratory volume in 1 s (FEV1) of >80% of predicted values for a population of similar 
height, weight, sex, age and race. All the subjects with asthma had physician-diagnosed mild 
and well controlled asthma and had lung function (percentage predicted FEV1) in the normal 
range with a mean (SEM) percentage predicted FEV1 of 106% (5%). With the exception of 
one subject, all those with asthma had a positive skin test to at least one aeroallergen that 
included house dust mite antigen, and had a positive methacholine challenge test (PC20 0.3–
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10 mg/ml). All the subjects with asthma used an inhaled β agonist (albuterol) on an as-
needed basis and maintained their allergy medicines (Advair, Singular, Claratin, Allegra, 
Zyrtec) during the course of the study. One asthmatic subject was on an inhaled steroid 
(Flovent, 100 μg twice daily).
Experimental design
The experimental design is shown in schematic form in fig 1. Subjects first inhaled 
radiolabelled particles (with deposition targeted to the central bronchial airways), with 
subsequent monitoring of mucociliary clearance by gamma scintigraphy. We then assessed 
in vivo uptake of inhaled radiolabelled particles by airway phagocytes recovered from 
induced sputum at 2 h following radioaerosol inhalation.
Radioaerosol inhalation and gamma scintigraphy
Radiolabelling and inhalation of particles and the subsequent gamma scintigraphy have been 
described previously.910 Using a controlled shallow breathing pattern, subjects briefly 
inhaled (<2 min, ≈20 μCi total deposited radioactivity) an aerosol of radiolabelled sulfur 
colloid (99mTc-SC) particles (0.22 μm aerodynamic diameter). Particle retention was 
monitored using sequential (2 min) gamma camera scans beginning immediately after 
inhalation and continuing for 2 h until sputum induction, with additional scans following 
sputum induction (40 min later) and at 24 h.
Figure 2 is a posterior scintigraphic image depicting a region of interest drawn over the right 
lung (large square). The degree of central (C) to peripheral (P) airway particle deposition 
was calculated as a central to peripheral (C/P) ratio of 99mTc activity using counts from the 
initial 2 min scan following aerosol inhalation and normalised to an 133xenon equilibrium 
scan.8 Whole lung particle retention/clearance and the average particle retention was 
calculated using data only from the right lung to avoid interference of activity from the 
stomach below the left lung.
Sputum induction and processing
Methods used for sputum induction (using inhaled hypertonic saline) and processing 
methods have been described in detail elsewhere.611 For safety reasons, patients with asthma 
must be pretreated with two puffs of albuterol (180 μg) before starting hypertonic saline 
inhalations. To avoid this as a possible confounder, both subjects with asthma and healthy 
subjects inhaled albuterol before sputum induction. A cell-enriched “select” sample was 
obtained using thumb forceps to pluck all visible clumps of cells and cell-rich mucus 
“plugs” from the raw sputum sample. Only the selected sputum was processed further with 
dithiothrietol (DTT) to remove mucus, since the non-selected secretions have a low 
proportion of phagocytes and a high proportion (>90%) of squamous epithelial cells.1213
Assessment of in vivo particle uptake
In vivo uptake of SC particles by airway phagocytes was estimated as the percentage of 
radioactivity associated with the cell pellet derived from the select sputum samples as 
previously described.6 A correction factor was applied to account for a small proportion of 
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free radiolabelled particles that tended to spin down with the cell pellet following low level 
centrifugation.6
Sputum cell analysis
Following determination of total and differential cell counts and cell viability, the remaining 
cells were used for flow cytometric assessment of cell surface phenotypes (mCD14, CD11b/
CR3, CD64/FcγRI, CD16/FcγRIII, CD80/B7.1, CD86/B7.2, HLA-DR) and in vitro 
phagocytosis assays using a FACSort flow cytometer and CellQuest Pro V.5.2 software 
(Beckton Dickenson, San Jose, California, USA), as previously described in detail.611 
Sputum cell populations were identified and gated based on light scatter properties and 
positive expression for CD45 (pan leucocyte marker) and further confirmed using CD16 
(PMN), mCD14 (monocytes), HLA-DR (macrophages) and CD3 (lymphocytes). Surface 
marker expression was measured as mean fluorescence intensity (MFI).
In vitro phagocytosis of FITC-labelled opsonised Saccharomyces cerevisiae zymosan-A 
bioparticles (3–4 μm physical diameter; Molecular Probes, Eugene, Oregon, USA) was 
assessed by measuring a shift in MFI of gated populations as an index of phagocytic 
activity. The number of particles engulfed per cell was estimated as the ratio of the MFI of 
the phagocytic cell population and the MFI of fluorescent zymosan particles. In addition to 
the macrophage population as a whole, phagocytosis by macrophage subpopulations (ie, 
mature and immature macrophages)14 were also evaluated separately.
Fluid phase cytokines (interleukin (IL)1α, IL1β, IL4, IL5, IL6, IL8, IL10, IL12p, IL13, 
tumour necrosis factor (TNF)α, interferon (IFN)γ, monocyte chemotactic protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1β, granulocyte-macrophage colony stimulating 
factor (GM-CSF), RANTES and eotaxin) were analysed using Luminex bead array 
technology (Luminex-100 Total System, Luminex Corporation, Austin, Texas, USA).
Statistical analysis
Based on our previous study6 where we found mean (SD) uptake of 27 (12)% in a group of 
healthy subjects without asthma, we calculated that we would be able to detect a change of 
±15% in in vivo percentage uptake (primary end point) with a total sample size of 18 (power 
= 0.75 for two-tailed test, p<0.05). Secondary exploratory end points included particle 
deposition and retention measurements, total and differential cell counts, flow cytometric 
measurements and sputum fluid-phase cytokine analysis. Specific variables were compared 
using two-tailed non-parametric statistics (Mann-Whitney U test and Wilcoxon sign rank 
test, as appropriate) and the significance of correlations was tested using Spearman’s 
correlation. Multivariate analysis was used to assess the dependence of average particle 
retention on subject type (healthy vs asthmatic) and C/P ratio of deposited activity, the latter 
variable included in the analysis because it has been shown previously that average particle 
retention is a function of deposition pattern in the lung.810 An overall level of p ≤ 0.05 was 
considered to be significant. All values are expressed as the mean (95% confidence interval, 
CI). GraphPad Prism V.3.1 statistical software (GraphPad Software) was used for statistical 
analysis, except that Systat V.5.2 for MacIntosh was used for multivariate analyses.
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One subject with asthma was unable to produce an adequate sample and was excluded from 
the analysis of sputum parameters. Total and differential cell counts and other sputum 
parameters for normal subjects and those with asthma are presented in table 1. No 
significant differences were detected between the two groups for any of the sputum 
parameters except for the percentage of eosinophils which, although very low, was 
significantly higher (p<0.001) in the subjects with asthma. Use of anti-inflammatory 
medications by asthmatic subjects may, at least in part, explain the slightly lower percentage 
of neutrophils in their sputum samples.
In vivo uptake of inhaled sulfur colloid (SC) particles
In vivo particle uptake by airway phagocytic cells (fig 3A) was significantly greater 
(p<0.01) in patients with asthma and was correlated with the percentage of sputum 
mononuclear phagocytes in the asthma group (r = 0.85, p<0.01) but not in the healthy 
subjects (fig 3B). Deposition of inhaled particles tended to be slightly more centralised in 
the airways of subjects with asthma (higher C/P ratio); however, the mean C/P ratio was not 
significantly different (p = 0.24) from that in healthy subjects. There was no significant 
correlation between the C/P ratios and in vivo particle uptake for normal subjects or those 
with asthma (fig 3C).
Although some amount of radioactivity could be detected in the non-selected sputum sample 
portions, there was no significant difference in the amount of radioactivity between healthy 
subjects and those with asthma (41.7% (95% CI 22.0% to 61.5%) vs 35.0% (95% CI 15.5% 
to 54.6%) respectively, p = 0.42). Much of this probably resulted from non-cell-associated 
free SC particles. Thus, their exclusion from uptake calculations on the selected sample may 
have resulted in an overestimation of uptake (up to 35–40% as an average relative amount). 
Separate experiments determined that DTT had no effect on the integrity of the 99mTc label 
to remain affixed to the SC particles.
Flow cytometry
Flow cytometric assays were performed on only 7/8 healthy subjects and 7/10 subjects with 
asthma owing to one of the following causes: a sputum sample could not be obtained, 
insufficient cells for adequate flow cytometric analysis, accidental loss of cell sample or 
instrument malfunction.
In vitro phagocytosis assays
It is unlikely that airway deposition of the very small (if not negligible) number of inhaled 
radiolabelled particles affected subsequent in vitro phagocytosis of the zymosan particles.
Sputum cell populations were discriminated on the basis of light scatter properties and 
phagocytosis was measured as a shift in the MFI for the gated population (fig 4). In vitro 
phagocytic indices were enhanced in subjects with asthma for all populations, with the 
exception of monocytes (table 2), due to a combination of a greater proportion of cells 
Lay et al. Page 5













taking up particles and an increased number of particles engulfed per cell. Within the 
macrophage population as a whole, the mean proportion of mature macrophages tended to 
be greater (albeit not significantly) in the patients with asthma (46.9% (95% CI 39.2% to 
54.5%) vs 38.7% (95% CI 18.0% to 59.4%), p = 0.32). The phagocytic index (MFI) of the 
mature macrophage population was significantly greater than the immature macrophage 
population in both the asthma (p = 0.016) and normal groups (p = 0.032), and they engulfed 
significantly more zymosan particles per cell than the immature macrophages (p = 0.016, 
both groups).
Cell surface markers
With the exception of CD64 and CD86, we found no significant differences in the cell 
surface marker expression (MFI) between subjects with asthma and healthy subjects. 
Expression of the co-receptor molecule CD86 was significantly increased on sputum 
macrophages from subjects with asthma compared with healthy subjects (263 (95% CI 126 
to 400) vs 141 (95% CI 92 to 190), p = 0.05) and CD64 expression was significantly lower 
on sputum monocytes derived from subjects with asthma (4.1 (95% CI 1.6 to 6.7) vs 11.4 
(95% CI 6.2 to 16.3), p<0.01). Although CD64 was also decreased on sputum macrophages 
from subjects with asthma, the difference was not significant (16.7 (95% CI 6.5 to 27.0) vs 
23.7 (95% CI 17.1 to 30.3), p = 0.07). However, exclusion of a single outlier in the asthma 
group would result in a significant difference from control values in the macrophage 
population (p<0.01).
Fluid phase components in sputum
There were no statistically significant differences between normal subjects and those with 
asthma for any of the fluid phase cytokines examined.
Whole lung particle retention and clearance
Whole lung particle clearance was significantly more rapid in subjects with asthma (p<0.01, 
fig 5A), as assessed by the average retention through the first 120 min after deposition (table 
3). Patients with asthma cleared particles more rapidly (steeper slope of retention curve) 
during the initial 50 min after deposition than healthy subjects (p = 0.021). Thereafter, the 
slopes of the retention curves were essentially parallel. The average particle retention over 
the 120 min monitoring period correlated significantly with the C/P ratio for subjects with 
asthma (r = −0.78, p<0.01, fig 5B) but not for healthy subjects. Whole lung particle retention 
was significantly less in subjects with asthma immediately following sputum induction and 
also at 24 h after deposition. The more rapid initial clearance (0–50 min) may be related to a 
more central deposition pattern (ie, trend towards higher C/P ratio) in subjects with asthma. 
However, even for a given C/P ratio, the subjects with asthma appear to have faster particle 
clearance (fig 5B), indicating that the more rapid clearance was not solely a function of 
more central deposition. Multivariate analysis of average retention (first 120 min) as a 
function of both C/P and subject type (healthy or asthmatic) showed a significant 
contribution from both variables (p<0.01 and 0.03, respectively, R = 0.78 for regression on 
both variables). Thus, the patients with mild asthma also have enhanced mucociliary 
clearance compared with those without asthma.
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Mucociliary clearance and phagocytosis of particles by airway macrophages are generally 
considered to be protective mechanisms which isolate and remove potentially noxious 
materials (including allergens) from the airways of normal individuals. We have shown that 
both of these airway defence mechanisms are enhanced in subjects with mild asthma 
compared with healthy controls.
A significant correlation between in vivo particle uptake and the proportion of macrophages 
in the sputum sample (fig 3) was evident only in the subjects with asthma, indicating that 
enhanced particle uptake was not strictly a function of macrophage numbers or percentages. 
Our in vitro findings (table 2) suggest that this could be the result of a higher state of 
activation of airway phagocytes (both macrophages and neutrophils) in subjects with 
asthma. Diminished expression of CD64 on sputum macrophages and the lack of a 
correlation between particle uptake and surface expression of either CD64 or CD11b suggest 
that factors other than Fcγ or complement receptor-mediated phagocytosis were responsible 
for the increased phagocytic activity in the subjects with asthma. For instance, scavenger 
receptors such as MARCO15 or CD206 (macrophage mannose receptor) and others can also 
mediate phagocytosis.16 Differences in the in vivo airway surface liquid milieu of patients 
with asthma—such as airway mucins,17 surfactant proteins,18 phospholipids,1920 
adenosine,2122 airway hydration or differential responses to albuterol or hypertonic saline—
may also have influenced particle-macrophage interactions.
Beta-2 adrenergic agonists delivered acutely are reported to increase mucociliary 
clearance,23 although others found little or no effect24 relative to placebo in patients with 
stable asthma. Because albuterol was not administered until just before sputum induction, it 
could not have influenced either in vivo particle uptake or mucociliary clearance of SC 
particles. The extent to which regular use of albuterol by our subjects with asthma may have 
influenced our measurements of either particle uptake or mucociliary clearance is unclear. 
Routine use of β2 agonists by our subjects with asthma may explain the decreased CD64 on 
their sputum macrophages.25 Nevertheless, it is unlikely that albuterol administered acutely 
contributed significantly to the observed differences in in vitro phagocytosis during the 
relatively short duration of sputum induction and processing.
We have considered that our results may have been subject to a sampling bias, due in part to 
slightly more central particle deposition in the asthma group which contributed to a more 
rapid initial rate of clearance (first 50 min) and lower average particle retention over the 2 h 
monitoring period. However, the proportion of the lung particle burden retrieved by sputum 
induction was not significantly different between the two groups (table 3), and neither 
regional deposition nor clearance kinetics was correlated with in vivo percentage uptake of 
SC particles, suggesting that sampling bias did not contribute to the difference in particle 
uptake. The movement of particles into other airway compartments, such as bronchial 
epithelium or interstitial locations, tends to occur over much longer periods2627 than the 
short 2 h time frame of our measurements and is unlikely to have played any significant role 
in our measurements.
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Our current in vitro findings parallel our previous findings5 and those of others,28 and 
demonstrate enhanced phagocytic capacity of airway macrophages in subjects with mild 
asthma. In our previous study, in vitro phagocytic activity of sputum macrophages was 
diminished in subjects with more severe asthma, similar to more recent findings in children 
with asthma.29 In addition, as shown in this study (fig 5) and previous studies, mucociliary 
clearance is enhanced in mild asthma528 but clearly depressed both with increasing disease 
severity30 and during acute exacerbations.31 These various studies demonstrate differences 
in the phagocytic functionality of sputum phagocytes, not only between healthy subjects and 
those with asthma but also between subgroups of patients with asthma which may be related 
to the severity of their disease.
Enhancement of in vivo particle uptake by airway phagocytes may play a protective role in 
patients with mild allergic asthma by sequestering allergens from Th2-committed mucosal 
dendritic cells. However, airway macrophages—like dendritic cells—also function as 
antigen presenting cells and have been shown to have constitutively altered functional528 
and phenotypic32 characteristics favouring a Th2 commitment and clearly play a role in the 
pathogenesis and maintenance of allergic airways disease.33 The constitutively increased 
expression of CD86 on macrophages in our cohort of patients with asthma supports the 
notion of enhanced antigen presenting capability and is consistent with these previous 
findings.
We acknowledge that a potential pitfall in this study is that we have compared numerous 
parameters in a relatively small number of subjects. Despite this, our conclusions regarding 
our stated primary end point (ie, differences in the in vivo uptake of inhaled particles) are 
supported by robust data and valid statistical evaluation. We note, however, that the sheer 
number of comparisons of secondary parameters could increase the probability of type 1 or 
type 2 statistical errors (false positive or false negative test) due to chance alone. In 
particular, statistical comparisons of those parameters having less robust differences and/or 
data derived from less than the full complement of subjects (eg, flow cytometric data for cell 
surface markers) may be more vulnerable to spurious findings.
CONCLUSION
In vivo uptake of inhaled particles and in vitro phagocytosis of opsonised bioparticles by 
airway macrophages are enhanced in subjects with mild allergic asthma compared with 
healthy subjects, as is mucociliary clearance of particles from the central airways. These 
findings prompt us to speculate that enhanced uptake of ambient particles and allergens 
coupled with enhanced constitutive expression of co-stimulatory molecules (ie, CD86) by 
Th2-biased airway mononuclear phagocytes could ostensibly lead to more efficient capture, 
processing and presentation of inhaled environmental allergens to Th2-committed T 
lymphocytes. Confirmation of this hypothesis requires additional research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Experimental design. Dynamic gamma scintigraphy was used to monitor thoracic radiation 
beginning immediately after inhalation of a radiolabelled particulate aerosol. Sputum 
induction was performed 120–160 min after inhalation. Additional static scintigraphic 
images were acquired immediately following sputum induction and again at 24 h after 
inhalation.
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Posterior gamma camera image of the whole lung showing regions used for determination of 
the central to peripheral (C/P) ratio and to evaluate the regional deposition of inhaled 
particles. The larger rectangle outlines the whole right lung as defined by a xenon 
equilibrium scan, while the smaller rectangle defines the central region (C), comprised of a 
higher proportion of large airways relative to the lung periphery (P). The very bright areas 
within the lung represent radioactivity concentrated in central airways.
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(A) Corrected in vivo percentage uptake of radiolabelled sulfur colloid particles was 
significantly greater in subjects with asthma than in healthy subjects (57.2% (95% CI 46.5% 
to 67.9%) vs 22.3% (4.9% to 39.6%), p<0.01). (B) Uptake of sulfur colloid particles was 
significantly correlated with the percentage of mononuclear phagocytes in induced sputum 
for subjects with asthma (r = 0.8500, p<0.01) but not for normal healthy subjects. (C) In 
vivo particle uptake was not a function of the site of deposition as assessed by the lack of 
significant correlation with the central to peripheral (C/P) ratios for either normal subjects or 
those with asthma. Normal subjects (open circles, n = 8); subjects with asthma (closed 
circles, n = 9).
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(A) Flow cytometry density plot showing the gating of sputum phagocytic cell populations 
based on light scatter properties. The right panel shows histograms of fluorescence intensity 
of gated macrophage populations (combined mature and immature macrophages) from (B) a 
normal subject and (C) a subject with asthma. Cells in the M1 region did not engulf particles 
while cells which engulfed particles had a higher mean fluorescence intensity (MFI) and 
shifted into the M2 region. Subjects with asthma were more efficient in phagocytosis of 
opsonised zymosan-A bioparticles (higher MFI) than healthy subjects. FSC, forward scatter; 
SSC, side scatter; PMN, polymorphonuclear leucocyte (neutrophil); MAC, macrophage.
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(A) Whole lung particle clearance proceeded more rapidly in subjects with asthma during 
the first 120 min after deposition than in healthy subjects, with asthmatic subjects clearing 
particles at a more rapid rate during the first 50 min after inhalation (see table 3). (B) The 
average retention during the first 120 min correlated significantly with the central to 
peripheral (C/P) ratio for subjects with asthma (r = −0.78, p<0.01) but not for normal 
healthy subjects. Normal subjects (open circles, n = 8); subjects with asthma (closed circles, 
n = 10).
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